NCT05321407
COVID-19 Vaccine Responses in PIDD Subjects
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Aug 30, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial completed
- Final enrollment: 12 participants (planned 100)
Notable Primary completion date: Dec 31, 2024 to Jun 30, 2026v5 Show 4 more changesShow less
- Trial status: Recruiting to Active, Not Recruiting
- Study completion date: Dec 31, 2024 to Jul 31, 2026
- Start date: Sep 24, 2021 to Sep 30, 2021
- Site details revised at 3 of 3 sites
- Notable Eligibility criteria revisedv4
- Minor Primary and study completion dates moved earlier to Dec 31, 2024
- Site contacts updated at 3 of 3 sites
- Notable Primary completion date: Sep 16, 2023 to Jul 1, 2025
- Study completion date: Sep 16, 2023 to Dec 31, 2025
- Collaborators: 3 to 4
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Spike (S) protein-specific T cell responses to stimulation with SARS-CoV-2 wild-type peptides (measured as a percentage of total T cells).
Timeframe: 2 years
Spike (S) protein-specific T cell responses to stimulation with SARS-CoV-2 alpha variant peptides (measured as a percentage of total T cells).
Timeframe: 2 years
Spike (S) protein-specific T cell responses to stimulation with SARS-CoV-2 beta variant peptides (measured as a percentage of total T cells).
Timeframe: 2 years
Spike (S) protein-specific T cell responses to stimulation with SARS-CoV-2 delta variant peptides (measured as a percentage of total T cells).
Timeframe: 2 years
Spike (S) protein-specific T cell responses to stimulation with SARS-CoV-2 omicron variant peptides (measured as a percentage of total T cells).
Timeframe: 2 years
Secondary (7)
S-specific T cell responses (as a percentage of total T cells) to SARS-CoV-2 vaccination in primary antibody deficiency over time.
S-specific T cell responses (as a percentage of total T cells) to SARS-CoV-2 vaccination in secondary antibody deficiency over time.
S-specific T cell responses (as a percentage of total T cells) to SARS-CoV-2 in infected participants.
S-specific T cell responses (as a percentage of total T cells) to SARS-CoV-2 in vaccinated participants.
Number of vaccinated participants who develop severe COVID-19 clinical outcomes.
Show 2 moreShow less
Number of infected participants who develop severe COVID-19 clinical outcomes.
Number of antibody deficiency participants who develop severe COVID-19 clinical outcomes.
Arms and interventions
X-linked agammaglobulinemia (XLA)
This study is a non-randomized observational cohort study of participants with XLA who have either received, as standard care, the Pfizer BioNTech BNT162b2 mRNA vaccine or the Moderna mRNA-1273 vaccine. In this protocol, vaccination is entirely voluntary and vaccines are not provided by the study.
Sites
3 sites in 1 country